(Q47760026)

5 February 2018

review article

1 reference

title

Translation of combination nanodrugs into nanomedicines: lessons learned and future outlook. (English)

1 reference

5 February 2018

1 reference

1 reference

Qingxin Mu

1

1 reference

5 February 2018

Jesse Yu

2

1 reference

5 February 2018

Lisa A McConnachie

3

1 reference

5 February 2018

John C Kraft

4

1 reference

5 February 2018

Yu Gao

5

1 reference

5 February 2018

Gaurav K Gulati

6

1 reference

5 February 2018

Rodney J Y Ho

7

1 reference

5 February 2018

publication date

29 December 2017

1 reference

5 February 2018

Journal of Drug Targeting

published in

1 reference

5 February 2018

page(s)

1-13

1 reference

5 February 2018

Modification of physicochemical characteristics of active pharmaceutical ingredients and application of supersaturatable dosage forms for improving bioavailability of poorly absorbed drugs.

cites work

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Intestinal permeation enhancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Nanoparticle-based targeted drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Role of nanotechnology in targeted drug delivery and imaging: a concise review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Recent technological advances in oral drug delivery - a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Imatinib (Gleevec) as a paradigm of targeted cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Cancer drug resistance: an evolving paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Improvement in solubility of poor water-soluble drugs by solid dispersion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Pharmacokinetic enhancers in HIV therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

The biochemistry of P-glycoprotein-mediated multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Therapeutic potential of nanocarrier for overcoming to P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Accelerating cancer therapy development: the importance of combination strategies and collaboration. Summary of an Institute of Medicine workshop.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Liposomal anthracyclines in metastatic breast cancer: clinical update

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Mechanisms of drug resistance in kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Origins and evolution of antibiotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Combination approaches to combat multidrug-resistant bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Nanoparticle-based combination therapy toward overcoming drug resistance in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Pharmaceutical nanotechnology for oral delivery of anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Nanoformulations for combination or cascade anticancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Cancer nanomedicine: progress, challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Mechanisms of resistance to HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Managing drug resistance in cancer: lessons from HIV therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Antiretroviral Drugs-Loaded Nanoparticles Fabricated by Dispersion Polymerization with Potential for HIV/AIDS Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

The end of AIDS: HIV infection as a chronic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Lipid–Drug Association Enhanced HIV-1 Protease Inhibitor Indinavir Localization in Lymphoid Tissues and Viral Load Reduction: A Proof of Concept Study in HIV-2287-Infected Macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Anti-HIV drug particles may overcome lymphatic drug insufficiency and associated HIV persistence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Nanoparticles with Precise Ratiometric Co-Loading and Co-Delivery of Gemcitabine Monophosphate and Cisplatin for Treatment of Bladder Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Co-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Long-acting three-drug combination anti-HIV nanoparticles enhance drug exposure in primate plasma and cells within lymph nodes and blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Investigational HIV integrase inhibitors in phase I and phase II clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Just caring: assessing the ethical and economic costs of personalized medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Genome remodelling in a basal-like breast cancer metastasis and xenograft

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Commentary on "Tumor Heterogeneity and the Biology of Cancer Invasion and Metastasis".

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Mutational landscape and significance across 12 major cancer types

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

The seed and soil hypothesis revisited--the role of tumor-stroma interactions in metastasis to different organs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

A new initiative on precision medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Accelerating Biomedical Discoveries through Rigor and Transparency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Microfluidics: a transformational tool for nanomedicine development and production

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Organoid cultures derived from patients with advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

A technology platform to assess multiple cancer agents simultaneously within a patient's tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Anti-tumor efficacy of c(RGDfK)-decorated polypeptide-based micelles co-loaded with docetaxel and cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Enhanced oral bioavailability of salmeterol by loaded PLGA microspheres: preparation, in vitro, and in vivo evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Combinational delivery of hydrophobic and hydrophilic anticancer drugs in single nanoemulsions to treat MDR in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

PEGylated lipid bilayer-supported mesoporous silica nanoparticle composite for synergistic co-delivery of axitinib and celastrol in multi-targeted cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Spatial Targeting of Tumor-Associated Macrophages and Tumor Cells with a pH-Sensitive Cluster Nanocarrier for Cancer Chemoimmunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Synergistic Cisplatin/Doxorubicin Combination Chemotherapy for Multidrug-Resistant Cancer via Polymeric Nanogels Targeting Delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Targeted delivery of platinum-taxane combination therapy in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Telodendrimer nanocarrier for co-delivery of paclitaxel and cisplatin: A synergistic combination nanotherapy for ovarian cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Using an RNAi Signature Assay To Guide the Design of Three-Drug-Conjugated Nanoparticles with Validated Mechanisms, In Vivo Efficacy, and Low Toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

pH-sensitive pullulan-based nanoparticle carrier of methotrexate and combretastatin A4 for the combination therapy against hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Nanoparticulate delivery system targeted to tumor neovasculature for combined anticancer and antiangiogenesis therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

A nanocapsular combinatorial sequential drug delivery system for antiangiogenesis and anticancer activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Doxorubicin delivered by a redox-responsive dasatinib-containing polymeric prodrug carrier for combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Co-delivery of daunomycin and oxaliplatin by biodegradable polymers for safer and more efficacious combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Spherical polymeric nanoconstructs for combined chemotherapeutic and anti-inflammatory therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Self-assembled nanoscale coordination polymers carrying oxaliplatin and gemcitabine for synergistic combination therapy of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Development and evaluation of oxaliplatin and irinotecan co-loaded liposomes for enhanced colorectal cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Efficient co-delivery of immiscible hydrophilic/hydrophobic chemotherapeutics by lipid emulsions for improved treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Pharmacokinetics and biodistribution of lonidamine/paclitaxel loaded, EGFR-targeted nanoparticles in an orthotopic animal model of multi-drug resistant breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2017.1419363

The challenge of patient adherence.

21 January 2018

1 reference

12 December 2020

Biomedical informatics in the education of physicians

1 reference

12 December 2020

Combination chemotherapy using core-shell nanoparticles through the self-assembly of HPMA-based copolymers and degradable polyester

1 reference

12 December 2020

Antitumor activity of electrospun polylactide nanofibers loaded with 5-fluorouracil and oxaliplatin against colorectal cancer

1 reference

12 December 2020

Codelivery of chemotherapeutics via crosslinked multilamellar liposomal vesicles to overcome multidrug resistance in tumor

1 reference

12 December 2020

The antibiotic resistance crisis: part 1: causes and threats

1 reference

12 December 2020

Nanopharmaceutics: phytochemical-based controlled or sustained drug-delivery systems for cancer treatment.

1 reference

12 December 2020

Precision medicine--personalized, problematic, and promising

1 reference

12 December 2020

Inhibition of P-glycoprotein Gene Expression and Function Enhances Triptolide-induced Hepatotoxicity in Mice

1 reference

12 December 2020

Combinatorial nanocarrier based drug delivery approach for amalgamation of anti-tumor agents in bresat cancer cells: an improved nanomedicine strategies

1 reference

12 December 2020

cRGD-installed docetaxel-loaded mertansine prodrug micelles: redox-triggered ratiometric dual drug release and targeted synergistic treatment of B16F10 melanoma.

1 reference

12 December 2020

Making individualized drugs a reality.

1 reference

12 December 2020

The molecular mechanisms of chemoresistance in cancers

1 reference

12 December 2020

10.1080/1061186X.2017.1419363

Identifiers

DOI

1 reference

5 February 2018

0 references

1 reference

5 February 2018